Department of Neurology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Kumamoto, Japan.
Department of Clinical Investigation, Kumamoto University, Kumamoto, Kumamoto, Japan.
Sci Rep. 2017 May 8;7(1):1579. doi: 10.1038/s41598-017-01775-4.
The relationship between familial amyloid polyneuropathy (FAP), which is caused by mutated transthyretin (TTR), and inflammation has only recently been noted. To determine whether inflammation is present in FAP carriers and patients, serum interleukin (IL)-6 concentration in 57 healthy donors (HD), 21 FAP carriers, and 66 FAP patients was examined, with the relationship between IL-6 and TTR assessed in each group by multiple regression analysis and structural equation models (SEM). Compared with HD, IL-6 concentration was elevated in FAP carriers (p = 0.001, 95% CI 0.398-1.571) and patients (p = 0.002, 95% CI 0.362-1.521). Further, SEM indicated a positive relationship between IL-6 and TTR in FAP carriers (p = 0.010, 95% CI 0.019-0.140), but not in HD and FAP patients. In addition, we determined whether TTR induces production of pro-inflammatory cytokines ex vivo. HD-derived CD14 + monocytes and induced pluripotent stem cell-derived myeloid lineage cells from a HD and FAP patient dose-dependently produced IL-6 under mutated and aggregated TTR conditions, compared with wild-type TTR. In conclusion, FAP carriers and patients are in an inflammatory state, with the presence of mutated TTR being a trigger of inflammation, especially in FAP carriers.
家族性淀粉样多发性神经病变(FAP)是由转甲状腺素蛋白(TTR)突变引起的,其与炎症之间的关系最近才被注意到。为了确定 FAP 携带者和患者是否存在炎症,检测了 57 名健康供体(HD)、21 名 FAP 携带者和 66 名 FAP 患者的血清白细胞介素(IL)-6 浓度,通过多元回归分析和结构方程模型(SEM)评估了每组中 IL-6 与 TTR 之间的关系。与 HD 相比,FAP 携带者的 IL-6 浓度升高(p=0.001,95%CI 0.398-1.571),患者的 IL-6 浓度也升高(p=0.002,95%CI 0.362-1.521)。此外,SEM 表明 FAP 携带者中 IL-6 与 TTR 之间存在正相关(p=0.010,95%CI 0.019-0.140),但在 HD 和 FAP 患者中则不存在。此外,我们还确定了 TTR 是否会在体外诱导产生促炎细胞因子。与野生型 TTR 相比,HD 来源的 CD14+单核细胞和由 HD 和 FAP 患者诱导的多能干细胞衍生的髓系细胞在突变和聚集的 TTR 条件下,可剂量依赖性地产生 IL-6。总之,FAP 携带者和患者处于炎症状态,突变的 TTR 是炎症的触发因素,尤其是在 FAP 携带者中。